Gold bars to be exempt from tariffs, White House clarifies
Vincent J. Angotti, the Chief Executive Officer of Talphera, Inc. (NASDAQ:TLPH), recently acquired a significant amount of the company’s common stock. According to a recent SEC filing, Angotti purchased 213,310 shares at a price of $0.586 per share, totaling approximately $124,999 - a notable investment in this $10 million market cap company. Following this transaction, his direct ownership of Talphera’s common stock increased to 403,769 shares. InvestingPro analysis indicates the stock is currently trading below its Fair Value, while maintaining a healthy balance sheet with more cash than debt and a strong current ratio of 3.56.
In addition to this purchase, Angotti was granted 61,000 restricted stock units, which will vest in three equal annual installments starting in April 2026. The SEC filing also reported that he received stock options to buy 365,000 shares, with a vesting schedule extending over four years from the grant date. These transactions highlight Angotti’s growing stake in Talphera as he continues to lead the company, which currently faces rapid cash burn challenges according to InvestingPro data. Discover more insights and 8 additional ProTips about Talphera in the comprehensive Pro Research Report.
In other recent news, Talphera Inc. reported its Q4 2024 financial results, emphasizing a strategic focus on cost management and clinical advancements. The company significantly reduced its combined R&D and SG&A expenses from $4.6 million in Q4 2023 to $3 million in Q4 2024. Talphera also secured up to $14.8 million in private placement financing, which will support its ongoing clinical trials. In a notable development, the FDA approved a reduction in the size of Talphera’s NEPHRO CRRT study, potentially accelerating its path to market. The study’s enrollment target was lowered from 166 to 70 patients, maintaining a 90% power to meet its primary endpoint. H.C. Wainwright maintained a Buy rating on Talphera stock with a $6 price target, following the FDA’s favorable update. The company plans to complete the NEPHRO CRRT study by the end of 2025, with a target for FDA approval in 2026. Talphera’s management remains focused on meeting study goals and advancing the development of Niyad, a lyophilized formulation of nafamostat.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.